A recent ASO with a similar mechanism has been developed and tested in a mouse model of Dravet syndrome and was shown to increase productive SCN1A mRNA transcripts sixfold and the voltage-gated sodium channel α subunit Nav.1.1 by over 50% in a dose dependent manner [27]. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.